Literature DB >> 16415920

Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.

W Kalow1.   

Abstract

Pharmacogenetics arose with studies of single genes, which had major effects on the action of particular drugs. It turned into pharmacogenomics through realization that the controls of most drug responses are multifactorial. Then, variable gene expression posed new problems, for example what do drugs do to genes, or how useful is any genetic pretesting of a person? A common disease may be caused by different groups of genes in different people, who therefore require different drugs for treatment. Personalized medicine is currently represented by a physician's attention to a patients age, sex, or ethnic background, that is groups showing smaller genetic variation than is typical for general humanity. Occasionally, there is also the use of single-gene pretesting of a patient before drug administration. Over time, improvements in multigenic testing promise to increase the role of personalized medicine. However, the many pharmacogenomic complexities, and particularly time-dependent changes of gene expression, will never allow personalized medicine to become an error-free entity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16415920     DOI: 10.1038/sj.tpj.6500361

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  29 in total

Review 1.  State-of-the-art and future directions in multilevel interventions across the cancer control continuum.

Authors:  Kurt C Stange; Erica S Breslau; Allen J Dietrich; Russell E Glasgow
Journal:  J Natl Cancer Inst Monogr       Date:  2012-05

Review 2.  Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.

Authors:  Eleanor Murphy; Francis J McMahon
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

3.  Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes.

Authors:  Sa Deepak; Kr Kottapalli; R Rakwal; G Oros; Ks Rangappa; H Iwahashi; Y Masuo; Gk Agrawal
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

4.  Clinical use of pharmacogenomic tests in 2009.

Authors:  Leslie J Sheffield; Hazel E Phillimore
Journal:  Clin Biochem Rev       Date:  2009-05

5.  Power to advocate for health.

Authors:  Kurt C Stange
Journal:  Ann Fam Med       Date:  2010 Mar-Apr       Impact factor: 5.166

6.  The paradox of primary care.

Authors:  Kurt C Stange; Robert L Ferrer
Journal:  Ann Fam Med       Date:  2009 Jul-Aug       Impact factor: 5.166

7.  On the readiness of physicians for pharmacogenomics testing: an empirical assessment.

Authors:  N Amara; J Blouin-Bougie; D Bouthillier; J Simard
Journal:  Pharmacogenomics J       Date:  2017-06-13       Impact factor: 3.550

Review 8.  How multi-organ microdevices can help foster drug development.

Authors:  Mandy B Esch; Alec S T Smith; Jean-Matthieu Prot; Carlota Oleaga; James J Hickman; Michael L Shuler
Journal:  Adv Drug Deliv Rev       Date:  2014-01-09       Impact factor: 15.470

Review 9.  The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.

Authors:  Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Cost-effectiveness of colorectal cancer screening - an overview.

Authors:  Iris Lansdorp-Vogelaar; Amy B Knudsen; Hermann Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-08       Impact factor: 3.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.